a r t i c l e s BRCA1 and BRCA2 are large phosphoproteins involved in DNAdamage repair through homologous recombination (HR) 1 . Although BRCA1 and BRCA2 share many interacting proteins, they show little homology and are thought to have different roles in HR and other processes 2 . BRCA1 is thought to be mainly a scaffold protein enabling interactions between different components of the HR machinery, whereas BRCA2 is directly involved in loading RAD51 to sites of damage or stalled replication forks 3 .
a r t i c l e s BRCA1 and BRCA2 are large phosphoproteins involved in DNAdamage repair through homologous recombination (HR) 1 . Although BRCA1 and BRCA2 share many interacting proteins, they show little homology and are thought to have different roles in HR and other processes 2 . BRCA1 is thought to be mainly a scaffold protein enabling interactions between different components of the HR machinery, whereas BRCA2 is directly involved in loading RAD51 to sites of damage or stalled replication forks 3 .
Heterozygous BRCA1 and BRCA2 inactivation mutations are associated with an increased risk to develop breast and ovarian cancers. These tumors often show loss of heterozygosity of the wild-type allele and mutation of the p53 tumor suppressor 4, 5 . Breast cancers that arise in BRCA1 mutation carriers are mostly high-grade tumors with the so-called triple-negative phenotype (that is, lacking expression of estrogen receptor and progesterone receptor and without amplification of human epidermal growth factor receptor (ERBB2/HER2)) 6 . BRCA1-associated tumors also express basal epithelial cell markers, such as cytokeratin 5/6 (ref. 7) , and cluster with basal-like breast cancers by gene expression profiling 8 . There is increasing evidence that a subset of sporadic tumors with a basal-like/triple-negative phenotype may have alterations in BRCA1-related pathways 9 . In contrast, BRCA2 mutation carriers develop mostly ER-positive breast cancers.
Whereas BRCA1 and BRCA2 function as tumor suppressors in breast and ovarian epithelium, homozygous deletion of BRCA1 or BRCA2 appears not to be tolerated during human or mouse development and in cultured primary cells such as mouse embryonic fibroblasts (MEFs) or stem cells 10 . Although concomitant deletion of p53 partially alleviates these phenotypes 11 , the incomplete rescue suggests the involvement of other factors in BRCA1/2 associated cancers. In search for such factors, using a candidate gene approach, knockout of 53BP1 was shown in a recent study 12 to rescue Brca1 hypomorphic MEFs and mice from premature senescence. 53BP1, a DNA-damage response (DDR) factor involved in both HR and nonhomologous end joining (NHEJ), is known to be an activator of p53 (ref. 13 ). However, 53BP1 also has p53 independent functions, and deletion of both 53BP1 and p53 has a synergistic effect on tumor development 14, 15 .
The observations in the Brca1 hypomorphic mutants raise some intriguing questions. First, will 53BP1 ablation also rescue cells completely deficient for BRCA1, a situation that is common in BRCA1-associated tumors? In contrast to Brca1-null mice, the Brca1 Δ11/Δ11 hypomorphic mice still express the natural BRCA1-Δ11 splice variant, which contains the conserved RING and BRCT domains 10 . The Brca1 Δ11 allele is functionally active, as evidenced by the fact that homozygous Brca1 Δ11/Δ11 mutants are viable on a p53 heterozygous background 16 . Other questions concern the mechanism by which deletion of 53BP1 rescues BRCA1-deficient cells and the potential relevance of 53BP1 status for BRCA1-associated cancers.
a r t i c l e s
In this work, we set out to explore these questions. We performed an unbiased transposon mutagenesis screen for factors that could restore normal growth of Brca1-null cells. Similar to the observations with Brca1 Δ11 hypomorphic mutants, clonal outgrowth of Brca1-null cells was rescued by a loss of function mutation of 53BP1. We show that cells lacking both BRCA1 and 53BP1 have a partially restored HR pathway. The clinical relevance of these findings is indicated by our data showing that 53BP1 expression is reduced in a subset of basal-like/triple-negative breast cancers and in BRCA1/2-associated breast cancers, suggesting positive selection for loss of 53BP1 function in these tumors.
RESULTS

53BP1 loss rescues proliferation defects of Brca1-null cells
Brca1 deletion in p53-proficient normal cells leads to a severe proliferation defect 17 . Cre/loxP-based conditional Brca1 knockout models would not be useful to screen for factors that enhance growth of BRCA1-deficient cells, as Brca1-deleted cells are rapidly eliminated and the culture is rapidly overtaken by BRCA1-proficient cells. To overcome this problem, we generated R26 CreERT2 Brca1 SCo/Δ mouse embryonic stem (ES) cells, which contain, in addition to a Brca1 Δ5−13 -null allele 18 , a Brca1 selectable conditional (Brca1 SCo ) knockout allele in which exons 5 and 6 are flanked by loxP recombination sites and a split puromycin resistance marker ( Fig. 1a and Supplementary  Fig. 1a) . Furthermore, these cells contain the CreERT2 gene targeted to the Rosa26 locus, leading to expression of a tamoxifen-inducible CreERT2 recombinase fusion protein 19 . Incubation of these cells with 4-hydroxytamoxifen (4OHT) resulted in nearly complete switching of the Brca1 SCo allele and consequent loss of BRCA1 protein expression ( Supplementary Fig. 1b,c) . Nonswitched R26 CreERT2 Brca1 SCo/Δ cells were effectively removed by puromycin selection (Supplementary Fig. 1e) .
We used the piggyBac transposon system 20 to perform an insertional mutagenesis screen for factors that rescue the proliferation defect of Brca1-deleted cells (Supplementary Data). We transfected R26 CreERT2 Brca1 SCo/Δ ES cells with plasmids containing an engineered piggyBac transposon and mouse codon-optimized piggyBac transposase. After induction of CreERT2-mediated deletion of the Brca1 SCo allele with 4OHT, we assayed for clonal survival of BRCA1-deficient ES cells under puromycin selection (Supplementary Fig. 2a ). The majority (294 out of 296) of surviving colonies analyzed contained both a switched and a nonswitched Brca1 SCo allele, indicating strong selection for allele duplication events (data not shown). Two clones that were completely Brca1 deleted showed identical patterns of piggyBac transposon integrations (Supplementary Fig. 2b) , one of which mapped to intron 16 of the 53bp1 gene (Supplementary Fig. 2c ) and correlated with abrogation of 53BP1 expression (Supplementary Fig. 2d) , consistent with the reported ability of 53BP1 deletion to abrogate senescence and cell death in Brca1 Δ11/Δ11 hypomorphic cells 12 . To validate the loss of 53BP1 expression as a survival factor in Brca1-null cells, we tested the effects of shRNA-mediated depletion of 53BP1 in R26 CreERT2 Brca1 SCo/Δ ES cells with two different shRNAs that efficiently suppressed 53BP1 expression, as determined by western blot analysis (Fig. 1b) . The robust clonal growth arrest of R26 CreERT2 Brca1 SCo/Δ ES cells induced by 4OHT treatment was abolished when 53BP1 was depleted with either shRNA (Fig. 1c) .
53BP1 loss rescues drug hypersensitivity of Brca1-null cells
A hallmark of BRCA1-deficient tumors is their cisplatin sensitivity 21 . Consistent with this, we observed enhanced cytotoxicity of cisplatin in our Brca1-deleted ES cells (Fig. 1d) . shRNA-mediated loss of 53BP1 fully abolished the cisplatin sensitivity induced by Brca1 inactivation (Fig. 1d) . We observed a similar reversal of drug sensitivity by 53BP1 depletion for mitomycin C (Fig. 1e) . Although shRNA-mediated inhibition of p53 suppressed the growth defects of Brca1-deleted cells (data not shown), it did not suppress cisplatin sensitivity, suggesting that p53 and 53BP1 provide distinct pathways for sustaining growth arrest in Brca1-deleted cells. a r t i c l e s monitored by western blotting (Fig. 2a) . In the absence of BRCA1, ES cells accumulate in G2 (Fig. 2b) , which could reflect a checkpoint response induced by accumulation of unrepaired DNA damage. This G2 arrest is abrogated in 53BP1-deleted cells but not in p53-depleted cells, suggestive of an ataxia-telangiectasia mutated (ATM)-dependent checkpoint activation for which 53BP1 is essential. Consistent with this, we observed an increase in 53BP1 expression levels in Brca1-deleted cells (Fig. 2a) . The less pronounced effect of p53 depletion on the G2 arrest is mirrored by the lower induction of p53 expression in response to Brca1 deletion, as detected by western blotting. p53 has a major role in the surveillance of chromosome integrity at the G1/S transition, although evidence for a relatively weaker p53-dependent checkpoint at the G2/M transition has also been reported 22, 23 .
53BP1 loss blocks DNA-damage responses in
To address the possibility that the loss of 53BP1 affects the DNA damage response (DDR) induced by Brca1 deletion, we used MEFs that were established from mice carrying a Brca1 SCo allele and a Brca1 Δ5−13 -null allele and immortalized by TBX2 overexpression. Transient expression of Cre recombinase from a self-deleting 'hit-and-run' (H&R) Cre retrovirus 24 resulted in efficient deletion of Brca1 exons 5 and 6 and loss of BRCA1 expression, as monitored by western blotting (Fig. 3a) . We detected concomitant loss of 53BP1 expression when MEFs were co-transduced with the H&R Cre and 53BP1 shRNA-encoding viruses. Upon Cre-mediated deletion of the Brca1 gene, we observed robust phosphorylation of the DNA-damage checkpoint kinase CHK2 as well as p53 accumulation, indicative of an ATM-dependent DDR in MEFs (Fig. 3a, +Cre, GFPsh). Similar to the G2 arrest, this ATM-dependent checkpoint response was markedly attenuated upon 53BP1 inhibition (Fig. 3a , +Cre, 53BP1sh1 and 53BP1sh2).
Consistent with unrepaired DNA damage being the cause of the observed G2/M arrest and checkpoint activation triggered by Brca1 deletion, we observed a marked increase in chromatid and chromosome breaks in BRCA1-deficient MEFs (Fig. 3b) . shRNA-mediated 53BP1 depletion in these cells led to a decrease in the occurrence of DNA breaks, reflected in diminished checkpoint responses.
In contrast to Brca1-knockout MEFs, proliferation of Brca2-knockout MEFs 25 was not rescued by shRNA-mediated depletion of 53BP1 (Fig. 3c) . In contrast, p53 inhibition efficiently restored the proliferative capacity of Brca2-deleted cells. Consistent with the role of 53BP1 in mediating checkpoint responses specifically in cells lacking Brca1, 53BP1 abrogation did not affect CHK2 phosphorylation in BRCA2-deficient MEFs (Fig. 3d) . This observation reflects the fundamentally distinct roles played by the BRCA1 and BRCA2 tumor-suppressor proteins in the DDR: whereas BRCA1 is required for the initial steps of the DDR response and signal amplification, BRCA2 functions downstream of the checkpoint signaling, promoting the HR pathway of DNA repair. Because 53BP1 acts during the early chromatin-remodeling events at the break, it is more likely to a r t i c l e s affect BRCA1-dependent signaling. In contrast, BRCA2 activation requires the damage signal generated at the break to be transduced downstream through at least two parallel pathways involving several response factors 26 . Thus, the loss of 53BP1 can be compensated by other regulatory mechanisms acting between the early events at the chromatin surrounding the break and the initiation of repair reactions. Although shRNA-mediated depletion of p53 rescues the proliferation defect of BRCA2-deficient cells, DDR activation shown by CHK2 phosphorylation persists. This suggests that CHK2-mediated p53 activation contributes to the senescence response induced by the loss of BRCA2. Consistent with the role of BRCA2 as the loader of RAD51 onto double-strand breaks (DSBs), the initiating step of recombinational DNA repair, we did not detect any rescue of RAD51 foci in BRCA2-deficient cells when either p53 or 53BP1 were depleted (data not shown).
Together, these results suggest that 53BP1 is required for efficient ATM-dependent checkpoint signaling to arrest cell-cycle progression in response to DNA damage accumulation in Brca1-deleted cells. Alternatively, 53BP1 loss might lead to more efficient DNA DSB repair and thereby reduce DDR activation.
53BP1 loss partially restores HR in Brca1-null cells
The observed abrogation of G2 accumulation, sensitivity to DNA crosslinkers and DDR may be due to a stimulation of BRCA1-independent DNA repair. Alternatively, checkpoint release might prevent the formation of DNA breaks by collapsing replication forks or allow the cells to continue cycling without actual repair of the damage. To investigate the effects of 53BP1 depletion on DNA repair, we analyzed RAD51 focus formation in Brca1 SCo/Δ and Brca1 Δ/Δ ES cells following treatment with ionizing irradiation (Fig. 4) . Analysis of these ionizing radiation-induced RAD51 foci revealed a diminished response upon deletion of Brca1 (Fig. 4a,c) , consistent with previous observations 27 . shRNA-mediated depletion of 53BP1 enhanced RAD51 focus formation in the absence of BRCA1, suggesting upregulation of HR in a BRCA1-independent manner. This process is not specific for ES cells, as we observed the same phenomenon in MEFs (Fig. 4b,d) .
To determine whether 53BP1 depletion rescues homology-directed repair (HDR) in BRCA1-deficient cells, we measured gene-targeting efficiencies in R26 CreERT2 Brca1 SCo/Δ ES cells with or without shRNAmediated depletion of 53BP1 or p53 using an isogenic Rb-targeting construct with a PGK-neo selection marker 28 . Whereas CreERT2-mediated deletion of Brca1 by addition of 4OHT abolished Rb gene targeting in R26 CreERT2 Brca1 SCo/Δ ES cells, this effect could not be reversed by shRNA-mediated depletion of p53 ( Table 1) . In contrast, we observed correct integration of the targeting vector at the Rb locus in 2 out of 160 53BP1-depleted R26 CreERT2 Brca1 Δ/Δ ES cell colonies compared to 8 out of 78 R26 CreERT2 Brca1 SCo/Δ colonies, suggesting that 53BP1 loss leads to partial restoration of HDR in Brca1-null cells. This notion was supported by gene-targeting experiments with a promoterless Pim1-neo targeting construct 29 , showing correct integration in 4 out of 47 53BP1-depleted R26 CreERT2 Brca1 Δ/Δ ES colonies compared to 9 out of 56 R26 CreERT2 Brca1 SCo/Δ colonies ( Table 1) . We conclude that depletion of 53BP1 restores HR activity in Brca1-null cells to 10-50% of that of BRCA1-proficient cells.
Basal-like breast cancers have low levels of 53BP1
The majority of BRCA1-associated tumors carry p53 mutations 30, 31 . It is known that p53 loss can at least partially rescue BRCA1-deficient cells 11, 32 . However, there may still be additional selection for aberrant expression of 53BP1, as suggested by our in vitro results and by the synergism in tumorigenesis observed in 53bp1 −/− p53 −/− knockout mice 14, 15 . Therefore, we analyzed levels of 53BP1 mRNA in a publicly We next calculated mean levels of 53BP1 expression for each breast cancer subtype (Fig. 5a) . We found the lowest 53BP1 expression levels in the BLC subclass. We have previously shown that a robust consensus clustering approach of breast cancer gene-expression data reveals two subclasses of BLC, which we labeled BA 1 and BA 2 (ref. 34 ). This approach also identifies two subclasses of HER2-positive cancers and three subclasses of luminal B tumors. We examined 53BP1 mRNA expression in these different subclasses in a combined dataset that includes the published datasets of two previous reports 33, 35 . In this combined dataset, we found that 53BP1 expression was clearly lowest in the BA 1 subtype of BLC (P < 0.0001 versus normal, P < 0.0002 versus BA 2 ) (Fig. 5b) . These data suggest that a biologically relevant subset of BLC has low 53BP1 expression. To validate this finding at the protein level, we assayed a set of 504 breast cancer specimens from the Yale cohort by immunohistochemistry on tissue microarrays. The clinical characteristics of the tumors in this collection are shown in Supplementary Table 1. Four hundred forty-four cases were evaluable for 53BP1 status. We scored a specimen as lacking 53BP1 staining if <10% of tumor cells showed nuclear staining with this antibody (Supplementary Fig. 3) . Out of 444 evaluable breast cancer specimens, we scored 65 (14.6%) as being negative for 53BP1.
53BP1 loss is associated with triple-negative phenotype
In the Yale cohort of 444 tumors, lack of 53BP1 staining correlated independently with lack of estrogen receptor expression, lack of progesterone receptor expression and lack of HER2 overexpression, as assessed by immunohistochemistry ( Table 2 ). There was a striking correlation between the absence of 53BP1 staining and the triplenegative phenotype, defined as being ER-, PR-and HER2-negative. Of the 63 tumors in the Yale cohort that lacked 53BP1 staining and for which ER, PR and HER2 status were available, 57 (90.5%) of these tumors were triple-negative tumors. Of the 132 triple-negative tumors assayed, 57 (43%) were 53BP1 negative, whereas of the 311 non-triple-negative tumors, only 6 (2%) had reduced 53BP1 staining. This correlation was statistically significant (P < 0.0001). The immunohistochemistry data are consistent with the gene-expression data and confirm that a subset of BLCs and triple-negative tumors have a profoundly decreased 53BP1 expression. Loss of 53BP1 was associated with age below 50, with most (67%) of 53BP1-negative tumors occurring in women less than 50 years old. There was no correlation with tumor size, lymph-node status or race.
53BP1 loss is associated with BRCA1/2 mutation status
To validate and extend the data from the Yale cohort, including assessment of 53BP1 protein expression in BRCA1/2-mutated familial breast carcinomas, we performed an independent larger-tissue microarray analysis on the Helsinki cohort of 1,187 patients ( Table 3) . We obtained these data using different 53BP1 antibodies, and the data were analyzed independently by separate pathologists (see Supplementary Fig. 4 for examples of 53BP1 staining patterns in the Helsinki cohort). Confirming the results obtained from the Yale cohort, lack of 53BP1 staining in the Helsinki cohort correlated independently with lack of estrogen receptor expression (P = 0.000004), lack of progesterone receptor expression (P = 0.003) and the triple-negative phenotype a r t i c l e s (P = 0.000004). In addition, the familial tumors from BRCA1/2 mutation carriers (79 tumors) showed the highest degree of aberrant 53BP1 reduction or loss compared to sporadic tumors (n = 374, P = 0.000003), familial carcinomas not attributable to BRCA1/2 mutations (n = 734, P = 0.001) or all non-BRCA1/2 tumors (n = 1,108, P = 0.0001). Both BRCA1-and BRCA2-associated tumors showed a significantly increased incidence of reduced 53BBP1 staining compared to non-BRCA1/2 tumors (P = 0.003 for BRCA1 and P = 0.008 for BRCA2). Overall, these results show that loss of 53BP1 is more frequent among the most aggressive and difficult-to-treat triplenegative tumors as well as in tumors with BRCA1/2 mutations.
53BP1 expression and distant metastasis-free survival
We analyzed the survival data from the Yale cohort. There was significant association between 53BP1 status and distant metastasisfree survival, with 53BP1-negative tumors having significantly lower metastasis-free survival (Fig. 5c ) (P = 0.001). As most tumors that lack 53BP1 have a triple-negative phenotype, we analyzed distant metastasis-free survival in triple-negative breast cancers stratified by 53BP1 status. Amongst the triple-negative tumors, those that lack normal 53BP1 staining have decreased metastasis-free survival (P = 0.039) (Fig. 5d) . As the cancers in this dataset were mostly earlystage, lymph node-negative cancers that did not receive any adjuvant treatment, these data suggest that early-stage triple-negative tumors with reduced 53BP1 may have a greater likelihood of metastasis in the absence of systemic treatment compared to triple-negative tumors with intact 53BP1.
DISCUSSION
BRCA1 is a large ubiquitously expressed protein that has a major role in DDR by HR. Its activity is extensively regulated by phosphorylation 36 , sumoylation [37] [38] [39] and interactions with many other proteins. Perhaps not surprisingly, BRCA1 is not only involved in HR but also in many other processes like cell-cycle control and transcriptional regulation 39, 40 . Despite its widespread expression and non-cell type-specific functions, mutations in BRCA1 are mainly associated with increased risk of breast and ovarian tumorigenesis. Loss of BRCA1 leads to severe proliferation defects in normal, noncancerous cells-for instance, leading to lethality during embryonic development. Therefore, it seems likely that there are survival factors that allow BRCA1-deficient tumor cells to expand. In an unbiased genetic screen, we found that loss of 53BP1 rescues clonal outgrowth of Brca1-null ES cells. This result confirms the recently described rescue of Brca1 Δ11/Δ11 hypomorphic mice by 53BP1 knockout 12 .
In addition, it shows that expression of the BRCA1-Δ11 splice variant is not required for rescue of BRCA1 deficiency by 53BP1 loss. This is important, as many human BRCA1-associated cancers are characterized by complete loss of BRCA1 expression. Further characterization indicated that BRCA1 and 53BP1 double-deficient cells are no longer hypersensitive to DNA cross-linking agents and do not spontaneously form DSBs or activate DDR. Suppression of ionizing radiation-induced CHK2 phosphorylation has been previously observed upon RNA interference-mediated 53BP1 depletion in U2OS cells 13 and in 53bp1 −/− MEFs 41 . Here we show that 53BP1 status specifically affects the spontaneous induction of CHK2 phosphorylation when BRCA1 is lost. Our results are consistent with recently reported data on 53BP1-mediated suppression of DNA resection at DSBs and accumulation of single-stranded DNA ends in BRCA1 and 53BP1 double-deficient cells 42 . In cell-free extracts, DNA damage-induced ATM activation and CHK2 phosphorylation are inhibited by 3′ single-stranded DNA overhangs generated during DNA-break processing in S/G2 (ref. 43) . The decreased CHK2 phosphorylation that we observed in 53BP1-depleted Brca1-null cells could therefore result from decreased ATM signaling due to increased DNA resection or from increased DSB repair. The latter possibility is supported by the restoration of ionizing radiationinduced RAD51 focus formation and the partial restoration of HR in 53BP1-depleted Brca1-null cells. Although our data suggest that a certain level of HR repair can take place in the absence of both BRCA1 and 53BP1, 53BP1-depleted Brca1-null cells remain HR defective, as gene-targeting frequencies in these cells are reduced by a factor of 2-10 when compared to wildtype cells. Consistent with this, BRCA1-deficient tumors show excellent responses to therapies exploiting a HR defect, such as platinum drugs 44 or PARP inhibitors 45 . Also, Brca1-mutated mouse mammary tumors are highly sensitive to treatment with PARP inhibitors 46 or platinum drugs 47 . Whereas human BRCA1-mutated tumors can develop resistance to carboplatin by genetic reversion of the BRCA1 mutation 48 -stressing the importance of BRCA1 function for HRmouse mammary tumor models with large deletions in Brca1 cannot employ this mechanism and remain sensitive to cisplatin or carboplatin, even after multiple rounds of treatment 47 . In contrast, Brca1 Δ11/Δ11 mouse mammary tumors, which only express the BRCA1-Δ11 isoform, readily become resistant to cisplatin despite the fact that Brca1 exon 11 sequences are irreversibly deleted 49 . This feature might be indicative of residual activity of the BRCA1-Δ11 isoform in HR.
At present, it is not clear whether 53BP1 loss contributes to development, therapy response and/or acquired resistance of BRCA1-deficient tumors. To explore this, we examined 53BP1 expression in independent cohorts of breast cancer patients from the US and Finland. These two tumor sets were analyzed by different antibodies and reviewed by independent pathologists using separate criteria, yet both cohorts showed a striking correlation of low 53BP1 expression levels with triple-negative a r t i c l e s tumors. Since most BRCA1-mutated breast cancers cluster in this subgroup, it was not unexpected to find that these tumors also lacked 53BP1 expression more often than other subsets of breast tumors. However, the often hormone receptor-positive BRCA2-associated tumors were also significantly enriched for 53BP1 aberrations. This may be indicative of a common selection for 53BP1 ablation in both types of HR-deficient breast cancers. This might occur via different routes, given the persistence of DDR activation and growth impairment in 53BP1-depleted BRCA2-deficient cells.
In conclusion, we have shown that 53BP1 loss alleviates the proliferation defect and DNA-damage hypersensitivity of Brca1-null cells and leads to partial restoration of HR in these cells. Furthermore, aberrant expression of 53BP1 is more common in BRCA1/2 associated breast cancers, which may hint at a role for 53BP1 loss in these tumors. 53BP1 is also lost in a subset of sporadic triple-negative breast cancers, suggesting a broader role for abnormalities in this pathway in breast tumorigenesis. Our results suggest that loss of 53BP1 may promote survival of BRCA1-deficient tumor cells after DNA damage induced by chemotherapy or irradiation. It is possible that 53BP1 loss may have different effects in BRCA1-deficient tumors versus sporadic triple-negative breast cancers. Regardless, 53BP1 might represent a candidate biomarker for predicting the response of HR-defective tumors to PARP inhibitors or platinum drugs.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
